Display options
Cite
Whale AD, Colman L, Lensun L, et al. Functional characterization of a novel somatic oncogenic mutation of . Signal Transduct Target Ther. 2017;2:17063doi: 10.1038/sigtrans.2017.63.
Whale, A. D., Colman, L., Lensun, L., Rogers, H. L., & Shuttleworth, S. J. (2017). Functional characterization of a novel somatic oncogenic mutation of . Signal transduction and targeted therapy, 217063. https://doi.org/10.1038/sigtrans.2017.63
Whale, Andrew D, et al. "Functional characterization of a novel somatic oncogenic mutation of ." Signal transduction and targeted therapy vol. 2 (2017): 17063. doi: https://doi.org/10.1038/sigtrans.2017.63
Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ. Functional characterization of a novel somatic oncogenic mutation of . Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017. PMID: 29279775; PMCID: PMC5740215.
Copy Download .nbib Format: NLM
Share it on

Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017.

Functional characterization of a novel somatic oncogenic mutation of .

Signal transduction and targeted therapy

Andrew D Whale, Lucy Colman, Letitia Lensun, Helen L Rogers, Stephen J Shuttleworth

Affiliations

  1. Karus Therapeutics Ltd., Genesis Building, Library Avenue, Harwell Campus, Oxfordshire, UK.

PMID: 29279775 PMCID: PMC5740215 DOI: 10.1038/sigtrans.2017.63

Abstract

Class I phosphoinositide 3-kinase (PI3K) enzymes have attracted considerable attention as drug targets in cancer therapy over the last 20 years. The signaling pathway triggered by class I PI3Ks is dysregulated in a range of tumor types, impacting cell proliferation, survival and apoptosis. Frequent oncogenic mutations of

Conflict of interest statement

All authors are either former or current employees of Karus Therapeutics Ltd.

References

  1. Cancer Res. 2016 May 15;76(10 ):2944-53 - PubMed
  2. Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11 - PubMed
  3. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8 - PubMed
  4. Nat Rev Drug Discov. 2014 Feb;13(2):140-56 - PubMed
  5. J Clin Pathol. 2015 Apr;68(4):253-7 - PubMed
  6. J Cell Sci. 2014 Mar 1;127(Pt 5):923-8 - PubMed
  7. Nat Med. 2005 May;11(5):507-14 - PubMed
  8. Cell. 2015 May 21;161(5):1215-1228 - PubMed
  9. J Biol Chem. 2010 May 14;285(20):14980-9 - PubMed
  10. Nature. 2010 Aug 12;466(7308):869-73 - PubMed
  11. Mol Cell. 2011 Mar 4;41(5):567-78 - PubMed
  12. Nat Biotechnol. 2016 Feb;34(2):155-63 - PubMed
  13. Cancer Res. 2016 Mar 1;76(5):1193-203 - PubMed
  14. Oncogene. 2016 Mar 3;35(9):1198-205 - PubMed
  15. Cancer Res. 2015 Dec 15;75(24):5341-54 - PubMed
  16. Nat Rev Drug Discov. 2009 Aug;8(8):627-44 - PubMed
  17. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13247-52 - PubMed
  18. Neoplasia. 2014 Feb;16(2):147-57 - PubMed
  19. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19897-902 - PubMed
  20. Cancer Discov. 2011 Nov;1(6):481-6 - PubMed
  21. Nature. 2008 Aug 7;454(7205):776-9 - PubMed
  22. JAMA Oncol. 2016 Dec 1;2(12 ):1565-1573 - PubMed
  23. Science. 2004 Apr 23;304(5670):554 - PubMed
  24. Nat Rev Mol Cell Biol. 2012 Feb 23;13(3):195-203 - PubMed
  25. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62 - PubMed
  26. Cancer Discov. 2016 Jul;6(7):714-26 - PubMed
  27. PLoS One. 2013 May 29;8(5):e63833 - PubMed
  28. Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1289-94 - PubMed
  29. Clin Cancer Res. 2017 Oct 1;23 (19):5981-5992 - PubMed
  30. Biol Cell. 2009 Jan;101(1):13-29 - PubMed
  31. J Biol Chem. 1998 May 29;273(22):13375-8 - PubMed
  32. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 - PubMed

Publication Types